Navigation Links
MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
Date:2/5/2008

Presentation will be webcast live and archived on Company's web site

GERMANTOWN, Md., Feb. 5 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver a corporate presentation on Monday, February 11, 2008, at 11:45 a.m. Eastern Time.

The presentation will take place as part of the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2008 at the Waldorf Astoria hotel in New York, New York. Dr. Rudnic's remarks will be available live on the MiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.middlebrookpharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Anthera Pharmaceuticals Forms Scientific Advisory Board
5. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
10. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: ... and commercialization of innovative biopharmaceutical products for companion animals, will ... at 8:30 a.m. ET to discuss financial results from the ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader ... for all SPIE attendees and Park customers on Feb. 27, 2017 ... the San Jose Convention Center. The luncheon will feature a talk on Automated ...
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of Lübeck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or ... neurodegenerative diseases, today announced it has issued a scientific white paper entitled “Results ... a series of commentaries from ProMIS’s scientific team offering insight into the Company’s ...
Breaking Biology Technology:
(Date:1/23/2017)... Jan. 23, 2017  The latest mobile market research ... have dropped dramatically. The quarterly average price of a ... $276 in Q4 2016.  There are now 120 sub-$150 ... $116, up from just 28 a year ago at ... to Maxine Most , Acuity Market Intelligence Principal, ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
Breaking Biology News(10 mins):